Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen

Trial Profile

A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Celecoxib (Primary) ; Ibuprofen; Naproxen
  • Indications Osteoarthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms PRECISION
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Jun 2018 According to a FDA media release, based on this study results, the U.S. Food and Drug Administration has approved a labeling supplement for Celebrex (celecoxib).
    • 30 Apr 2018 Planned number of patients changed from 24200 to 24222.
    • 24 Apr 2018 Results published in the Journal of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top